Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2018—Spot Imaging introduced its CytoXpress, an FDA-approved consultation method that lets clinicians and technologists transmit a live, interactive image stream directly to the user’s computer, eliminating the travel and wait time associated with on-site consults.
February 2018—Vector Laboratories introduced the TrueView Autofluorescence Quenching Kit for removing unwanted fluorescence in formalin-fixed, paraffin-embedded tissue samples, blood cells, and structural elements such as collagen and elastin.
February 2018—Ortho Clinical Diagnostics and EKF Diagnostics announced an agreement that allows Ortho customers to access EKF’s Beta-Hydroxybutyrate LiquiColor Assay, a CLIA moderate-complexity test for use on Ortho’s Vitros 4600 Chemistry System and Vitros 5600 Integrated System.
February 2018—LGC Maine Standards announced the release of its Validate SP2 linearity and calibration verification kit. The Validate SP2 kit, in a human serum matrix, evaluates albumin, ceruloplasmin, C-reactive protein, haptoglobin, prealbumin, and rheumatoid factor. Each kit offers five distinct concentrations covering the reportable ranges of Roche Cobas analyzers.
February 2018—MedTest announced the commercial availability of four forensic use only urine drug tests for use on its BS-200, BS-480, and BA-800M chemistry analyzers. The four new assays are DRI Fentanyl, Cedia AB-PINACA (spice K2), Cedia UR-144/XLR-11 (spice K2), and DRI Ethyl Glucuronide.
February 2018—Approximately 250 professionals attended an inspector training program organized by National Reference Laboratory, part of Mubadala’s network of health care providers, and the College of American Pathologists. Faculty included members of the CAP leadership as well as worldwide and local experts experienced with the quality accreditation process.
February 2018—Oasis Diagnostics has launched a testing service, through its Oasis Research Laboratory, for salivary hormone biomarker assessment using discreet panels. The service aims to relieve some of the complexity inherent in testing for biomarkers in the research setting.
February 2018—Sekisui Diagnostics and Mesa Biotech announced a strategic alliance to distribute the Mesa Biotech POC molecular system for Flu A/Flu B. Sekisui Diagnostics will assume exclusive distribution of the Mesa Biotech POC system in the United States and Canada, pending FDA clearance.
February 2018—Illumina introduced its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD-marked next-generation-sequencing system. Illumina also announced that the intended use for the MiSeqDx instrument now includes the use of DNA libraries generated from formalin-fixed, paraffin-embedded tissues.
February 2018—Qiagen and DiaSorin announced a partnership in which Qiagen’s QuantiFeron-TB diagnostic test will be added to the menu of DiaSorin’s Liaison family of analyzers, enabling customers of both companies to process QuantiFeron-TB Gold Plus, a fourth-generation assay for latent tuberculosis detection, on Liaison platforms. QFT-Plus is the first assay from the QuantiFeron portfolio that is planned to be adapted for use on the Liaison systems, with additional assays under consideration.
